TECH Signal 309
Shirts Delivered to 77 Committee Desks, No Markup, No Reply
↗
T-shirts bearing the slogan For Babies’ Sake, Test for Botulism in Infant Formula were hand-delivered to 77 congressional offices, including all members of the House Energy and Commerce Committee and Senate HELP Committee, to urge markup of H.R. 7867, the Infant Formula Safety Modernization Act of 2026.
The lack of response from congressional offices and committees highlights a stalled legislative effort to strengthen infant formula safety testing, despite confirmed outbreaks and pending regulatory action that could prevent future infant botulism cases.
Written by elseif from the cluster below · every claim links back to a sourceThe three things worth knowing
T-shirts were delivered to every member of the House Energy and Commerce Committee and Senate HELP Committee, two per office, as part of a coordinated advocacy push.
No markup hearing has been scheduled and no office has responded to the shirts, follow-up letters, or the fourteen families' statements attached to the committee file.
The FDA has not updated testing requirements for infant formula to include Clostridium botulinum, despite genomic evidence linking the outbreak to Nara Organics and ByHeart products.
THE READ
What the cluster adds up to.
The event marks a concrete legislative stall: despite physical delivery of advocacy materials to every relevant committee office, no hearing has been called and no markup of H.R. 7867 has occurred, leaving the bill in procedural limbo.
The cost of inaction is measurable in public health risk, as the FDA continues to enforce a testing rule that excludes Clostridium botulinum, the organism responsible for the largest infant botulism outbreak in U.S. history, which led to 52 hospitalizations and expensive antitoxin treatments.
The failure to engage with the fourteen families' statements and to hold an oversight hearing means the legislative process has ignored both constituent pressure and laboratory evidence that could inform a regulatory fix.
The difference between feeds lies in their emphasis: one highlights the physical delivery and lack of response, another underscores the regulatory gap and the FDA's inaction, while a third notes the historical precedent of using public pressure to force committee action, showing that no single source contains the full picture of stalled momentum and missed opportunities.
Written by elseif from the cluster below · checked for specifics the sources never containedTHE CLUSTER